Furthermore, Sal B synergized effectively with anti‐PD‐1 immunotherapy in vivo, highlighting the therapeutic potential of targeting the ZFPL1‐ASS1 pathway in combination with immune checkpoint blockade for advanced CRC. This evidence concerns the gene ASS1 and colorectal carcinoma.